Our clinical research study for people who are experiencing
memory loss, or have been diagnosed with
Mild Cognitive Impairment (MCI or MCI-AD),
Probable/Early Alzheimer’s disease, or
Mild-Moderate Alzheimer’s disease is now closed to
new participants. Results of the initial 12-month
blinded phase of the trial are expected in mid-2022.
THANK YOU FOR YOUR INTEREST AND PARTICIPATION
This clinical research study aims to evaluate an investigational drug in men and women with Alzheimer’s disease (AD). Currently, a limited number of approved treatments help with the symptoms of AD, but do not stop the disease from progressing. By reducing the build-up of ‘tau tangles’ in the brain, the main driver of AD, researchers believe that this investigational drug could help slow disease progression and enhance the quality of life of people living with AD.
Approximately 500 people in over 100 study centers across the United States, Canada, UK, France, Belgium, Italy, Spain and Poland are taking part in this study. The results will help determine whether this investigational drug can advance to the final stages of clinical development.
This study involves patients across a range of cognitive impairment, assessed by reference to an MMSE (Mini-Mental State Exam) score, involving those with very mild symptoms to those with moderate symptoms. A set number of people in three different score ranges have joined the study.
Find out more about clinical research and the LUCIDITY Study in the video below:
Clinical research studies are conducted to evaluate an investigational drug and determine how effective it is in treating a specific disease. These studies are performed according to strict governmental and ethical guidelines. Once these studies are completed, government agencies review the information then decide whether the drug should be made available for public use.
The 3 phases of clinical research studies
The drug being studied is given to a small group of healthy volunteers. Researchers look to see how much is safe to take and how the human body responds when it receives the drug.
The drug is given to a small group of people with the target disease, or condition it is trying to treat. In this phase, researchers evaluate the right dose amount and begin to test the safety and effectiveness of the selected dose of the drug.
Researchers test the safety and effectiveness of the drug in a larger group of participants over a longer period of time, compared with Phase 2. Sometimes comparisons are made between the drug being studied and other medications that are already approved for the same purpose.
Some trials cover aspects from more than one phase. The LUCIDITY Study is in Phase 3. To learn more about this particular clinical research study, visit ClinicalTrials.gov.
Scroll down to our FAQs section to see some of the most frequently asked questions about clinical trials.
Use the interactive map below to view centers in your area involved in the study. Simply enter your zip/postal code below and click “SEARCH”.
You can also find a full list of sites on Clinicaltrials.gov. Please note that no sites are actively recruiting right now as we have reached recruitment targets. The study is now closed to new participants.
The following are some frequently asked questions (FAQs) about this clinical research study. Click on a question below to reveal the answer.
Thank you for your interest and participation. Results of the initial 12-month blinded phase of the trial are expected in mid-2022.